



COMPREHENSIVE RESEARCH REPORT ON THE DIAGNOSIS, PATHOPHYSIOLOGY, AND PHARMACOLOGICAL TREATMENT OF GUILLAIN-BARRÉ SYNDROME

Mahammad Zaid Md Atik^{*1}, Yash Nitin Pawar², Kshitija Vinod Fopase³, Mukesh M Nikhade⁴

¹*Researcher/Pharma Student, Jagadambha Institute Of Pharmacy And Research, India
mahammadzaid31@gmail.com

²Pharmacist, Yashodeep Institute Of Pharmacy, India, yash.p062524@gmail.com

³Pharmacist, Jagadambha Institute Of Pharmacy And Research, India, fopase27k@gmail.com

⁴Asso. Prof., Siddhivinayak college of pharmacy Warora, India, nikhademukesh09@gmail.com

***Corresponding Author:** Mahammad Zaid Md Atik

Researcher/Pharma Student, Jagadambha Institute Of Pharmacy And Research, India
mahammadzaid31@gmail.com

Abstract

Guillain-Barré Syndrome (GBS) represents a complex, heterogeneous spectrum of acute, immune-mediated inflammatory polyradiculoneuropathies. Recognized globally as the foremost cause of acquired, rapid-onset neuromuscular paralysis, the syndrome demands emergent neurological intervention and sophisticated intensive care management. The clinical manifestations of GBS are remarkably diverse, spanning from the classical presentation of symmetrical ascending paresis and profound areflexia to highly localized cranial nerve dysfunctions, severe sensory ataxia, and life-threatening autonomic nervous system instability.

Epidemiological data indicate an annual global incidence ranging between 1 and 2 cases per 100,000 person-years, translating to approximately 100,000 newly diagnosed cases worldwide each year. Historically conceptualized as a singular demyelinating pathology, contemporary neuroimmunology has stratified GBS into several distinct clinical, electrophysiological, and pathological variants. These primarily encompass Acute Inflammatory Demyelinating Polyradiculoneuropathy (AIDP), Acute Motor Axonal Neuropathy (AMAN), Acute Motor Sensory Axonal Neuropathy (AMSAN), and Miller Fisher Syndrome (MFS). The recent international guidelines have substantially refined the diagnostic criteria, prognostic modeling, and therapeutic pathways for these variants. This exhaustive research report meticulously dissects the current scientific and clinical understanding of Guillain-Barré Syndrome. It explores the intricate pathophysiology driving the syndrome, emphasizing the precise mechanisms of molecular mimicry at the B-cell level triggered by antecedent infections such as *Campylobacter jejuni*. The report provides a critical, evidence-based appraisal of the current diagnostic frameworks, including cerebrospinal fluid analysis and electrodiagnostic testing. Furthermore, it conducts an extensive comparative analysis of the primary standard-of-care pharmacotherapies: Intravenous Immunoglobulin (IVIG) and Therapeutic Plasma Exchange (PE/PLEX). Finally, the report investigates the horizon of emerging, biologically targeted therapeutics which hold the potential to fundamentally transform the management of this devastating condition.

Keywords: Guillain-Barré Syndrome, molecular mimicry, *Campylobacter jejuni*, Intravenous Immunoglobulin (IVIG), Therapeutic Plasma Exchange, complement pathway.

1 INTRODUCTION

Guillain-Barré Syndrome (GBS) operates as an acute-onset, predominantly self-limiting, immune-mediated disorder of the peripheral nervous system [1]. The quintessential clinical presentation involves a rapidly progressive, bilateral, and relatively symmetrical muscle weakness. This paresis typically originates in the distal lower extremities and ascends proximally, eventually compromising the upper extremities, bulbar musculature, and muscles of respiration [2]. This progressive motor deficit is characteristically accompanied by hyporeflexia or complete areflexia. While motor symptoms dominate the clinical picture, sensory disturbances—such as distal paresthesias and severe radicular pain localized to the lumbar or intercostal regions—are frequently present, particularly in the initial stages of the disease [3].

The introduction clearly states the object of your work, its scope and the main advances you are reporting. It gives reference to relevant results of previously published work. A theoretical and experimental methods section gives sufficient information about the research carried out by the researcher. The results and discussion section states your results and their potential implications. In the discussion you should state the impact of your results compared with recent work.

The primary objective of this exhaustive review is to synthesize the vast, rapidly evolving body of literature surrounding Guillain-Barré Syndrome, effectively bridging the gap between foundational neuro-immunological science and immediate bedside clinical application [4]. By meticulously analyzing the updated guidelines set forth by international neurology societies, this paper aims to provide clinicians, researchers, and students with an unparalleled, deep-dive resource detailing every facet of the disease lifecycle—from initial infectious trigger to long-term rehabilitation [5]. The expanded scope of this manuscript involves a deep dive into historical contexts, microscopic biological interactions, and long-term socioeconomic impacts.

2 EPIDEMIOLOGICAL PROFILE AND DEMOGRAPHICS

2.1 Global Incidence and Demographic Distribution

Epidemiological surveillance indicates that GBS occurs across all global populations and age demographics, though its incidence is not uniform. The condition possesses an overall lifetime likelihood of acquisition of approximately 1 in 1,000 individuals [6]. While children are susceptible, representing the most common cohort for acute flaccid paresis in the pediatric demographic, the incidence of GBS demonstrates a definitive positive correlation with advancing age, reaching its peak incidence between the sixth and eighth decades of life [7].

Interestingly, GBS defies the epidemiological norms of most autoimmune diseases. Unlike multiple sclerosis, systemic lupus erythematosus, or rheumatoid arthritis, which exhibit strong female predilections and strong human leukocyte antigen associations, GBS lacks significant HLA associations, does not follow a relapsing-remitting course, and predominantly affects males [8]. In the general population, the male-to-female ratio is approximately 1.5 to 1, a preponderance that is further amplified among hospitalized cohorts suffering from severe acute disease.

2.2 Regional and Seasonal Variations

Profound geographic and ethnic disparities exist regarding the prevalence of specific GBS subtypes. In North America and Europe, the demyelinating variant accounts for up to 90 percent of all incident cases, mirroring classic historical descriptions of the syndrome [9]. Conversely, in distinct geographical regions, including China, Japan, and the Indian subcontinent, the axonal variant is highly prevalent [10].

In India specifically, epidemiological literature indicates that the incidence rates of demyelinating and axonal forms are virtually equal. Furthermore, GBS in these regions manifests at a considerably

younger average age compared to Western populations. The onset of GBS in these populations exhibits distinct seasonal peaks, historically clustering between June and July, and subsequently between September and October [11]. These seasonal fluctuations are tightly correlated with local environmental factors, specifically the peak transmission periods of enteric bacterial pathogens and viral respiratory illnesses, which serve as the primary immunologic triggers for the syndrome [12].

3 PATHOPHYSIOLOGY AND IMMUNOPATHOGENESIS

The pathogenesis of Guillain-Barré Syndrome is orchestrated by a complex intersection of environmental microbial triggers, host genetic susceptibility, and an aberrant autoimmune targeting of the peripheral neuroanatomy. The foundational mechanism driving the syndrome is post-infectious autoimmunity, wherein the adaptive immune system fails to effectively differentiate between exogenous pathogenic antigens and endogenous host tissues [13].

3.1 Antecedent Infections and Polymicrobial Causation

Clinical histories reveal that approximately 70 percent of GBS patients experience a definitive precursor illness—most frequently an upper respiratory tract infection or an episode of acute bacterial gastroenteritis—occurring 3 to 30 days prior to the onset of objective neurological deficits [14]. GBS is elicited by a diverse array of microbial pathogens, speaking to the notion of polymicrobial disease causation.

Recognized viral triggers intricately linked to GBS include Cytomegalovirus, Epstein-Barr virus, Hepatitis E virus, human influenza viruses, Human Immunodeficiency Virus, and the Zika virus [15]. However, the most rigorously documented and pathogenically consequential trigger is the Gram-negative bacterium *Campylobacter jejuni*, which alone is responsible for approximately 30 percent of all global GBS cases [16].




Figure 1: **Structural Flow chart of Immunopathogenesis.** The stepwise immunological cascade leading from an initial enteric infection to terminal peripheral nerve destruction.

4 MOLECULAR MIMICRY AT THE B-CELL LEVEL

The pathophysiological cascade initiated by *C. jejuni* serves as the quintessential biological model for understanding GBS. This cascade is driven by structural molecular mimicry, representing one of the

best-supported and most rigorously verified examples of true molecular mimicry at the B-cell level in any human autoimmune disease [17].

4.1 The Role of Gangliosides

Peripheral nerves are heavily invested with gangliosides—a family of sialylated glycosphingolipids that are highly concentrated in the pre-synaptic membranes of the neuromuscular junction and specifically within the axolemma at the nodes of Ranvier [18]. These gangliosides (including GM1, GD1a, and GQ1b) are structurally essential for maintaining rapid, saltatory nerve conduction and axoglial stability.




Figure 2: **Anatomy of a Peripheral Nerve in GBS.** The diagram demonstrates the specific target sites for autoimmune destruction, focusing either on the Myelin Sheath (in AIDP) or the exposed axolemma at the Node of Ranvier (in AMAN).

4.2 The Bacterial Deception

Certain virulent strains of *C. jejuni* possess a specific genetic composition that functions in sialic acid biosynthesis and transfer, allowing them to express lipo-oligosaccharides (LOS) on their outer bacterial membrane that are molecularly identical to human nerve gangliosides [19].

It is exclusively the carbohydrate portion of the LOS, rather than the lipid matrix, that executes this structural mimicry. During the acute phase of the gastrointestinal infection, the host's innate immune system is violently triggered via Toll-like receptor signalling. The structural homology bypasses normal peripheral B-cell tolerance mechanisms, leading to a robust generation of cross-reactive autoantibodies—primarily of the highly active IgG1 and IgG3 subclasses [20].

The specific structural target of these autoantibodies directly dictates the resulting clinical variant of the syndrome. Lipo-oligosaccharides from *C. jejuni* isolated from patients presenting with pure motor GBS mimic GM1 and GD1a. Conversely, LOS from *C. jejuni* isolated from patients developing the ataxic Miller Fisher Syndrome variant closely mimic GQ1b [21].

5 CLINICAL SUBTYPES AND PHENOTYPIC SPECTRUM

GBS is not a monolithic entity but rather a collection of primary inflammatory neuropathies characterized by substantial clinical and pathological heterogeneity.

5.1 Primary Variants

1. Acute Inflammatory Demyelinating Polyneuropathy (AIDP):

This is the classic form of GBS, representing the vast majority of cases in Western nations. The primary anatomical target is the myelin sheath and the Schwann cells that produce it [22]. The clinical presentation is defined by ascending symmetric weakness, profound areflexia, and significant sensory loss or pain. Because the central axon is often spared early in the disease, recovery via remyelination is generally robust, though slow.

2. Acute Motor Axonal Neuropathy (AMAN):

Highly prevalent in Asia and intimately linked to *C. jejuni* infections, AMAN completely bypasses the myelin sheath. Pathogenic autoantibodies (Anti-GM1, AntiGD1a) directly attack the axolemma at the nodes of Ranvier on motor nerves exclusively [23]. Patients present with pure motor weakness and rapid onset of paralysis, notably lacking the sensory numbness or tingling seen in AIDP. Because the central neural wire is destroyed, wallerian degeneration occurs, leading to prolonged and difficult recovery.

3. Acute Motor-Sensory Axonal Neuropathy (AMSAN):

Representing the most severe and destructive end of the GBS spectrum, AMSAN involves autoimmune attacks on the axolemma of both motor and sensory peripheral nerves. Patients suffer from profound, rapid total body paralysis combined with a complete loss of all sensation. The structural neural damage is catastrophic, and patients frequently endure permanent, lifelong disabilities regardless of acute therapeutic interventions [24].

4. Miller Fisher Syndrome (MFS):

MFS is a highly unique regional variant characterized by a remarkably specific clinical triad: ophthalmoplegia (paralysis of the extraocular muscles), severe sensory ataxia (profound loss of balance and coordination), and areflexia, often occurring without overt limb weakness initially. The underlying pathomechanism is highly defined, with over 90 percent of patients possessing high titers of Anti-GQ1b antibodies, which target gangliosides heavily concentrated in the cranial nerves [25].

6 DIAGNOSTIC GUIDELINES AND INVESTIGATIONS

Given the profound clinical heterogeneity of GBS and the absence of a singular, universally definitive biological marker capable of capturing all variants, diagnosis has historically relied on core clinical criteria, subsequently revised by international consensus groups.

6.1 Clinical Core Criteria

The absolute mandatory clinical criteria required for establishing a diagnosis of typical motor-sensory GBS include:

- Progressive motor weakness observed in more than one limb.
- Hyporeflexia or complete areflexia in the affected limbs.
- Temporal progression of symptoms that definitively reaches its clinical nadir within a maximum of four weeks.

The strict adherence to the four-week progression window is supported by robust epidemiological data demonstrating that the vast majority of patients experience continuous progression for no longer than two weeks. If neurological deficits continue to progress smoothly or in a stepwise fashion beyond eight weeks from the onset, clinicians must evaluate for acute-onset chronic inflammatory demyelinating polyradiculoneuropathy, which mandates fundamentally different long-term management [26].

6.2 Cerebrospinal Fluid (CSF) Analysis

Lumbar puncture and subsequent cerebrospinal fluid analysis serve as vital diagnostic adjuncts. The hallmark laboratory finding in GBS is cytoalbuminologic dissociation, defined as an elevated CSF protein concentration occurring in the distinct absence of a significant cellular increase (pleocytosis) [27]. However, CSF protein levels may remain entirely within normal physiological limits during the initial days following symptom onset. Therefore, a normal early CSF protein assessment does not exclude the diagnosis of GBS and should not delay life-saving immunotherapy.

6.3 Electrophysiological Testing

Electrodiagnostic testing is strongly advised to confirm the presence of an acute peripheral neuropathy and objectively assess the extent of axonal versus myelin damage. Characteristic electrophysiological

abnormalities in classical AIDP include prolonged F-wave latencies, delayed distal motor wave latencies, and reduced compound muscle action potential amplitudes. Importantly, treatments must never be delayed pending electrophysiological classification [28].

7 FIRST-LINE PHARMA COTHERAPY: INTRAVENOUSIMMUNOGLOBULIN

The primary goal of acute pharmacological intervention in GBS is to rapidly halt the immune-mediated destruction of peripheral nerves. There are two equally efficacious pillars of definitive pharmacotherapy: Intravenous Immunoglobulin (IVIG) and Therapeutic Plasma Exchange (PE/PLEX). Neither therapy holds the biological capability to reverse existing axonal degeneration; rather, they serve to rapidly arrest the aberrant inflammatory cascade.

IVIG is currently the predominant, preferred first-line therapy utilized in the vast majority of developed healthcare systems globally due to its robust clinical efficacy, highly standardized protocols, and relative ease of administration compared to extracorporeal therapies [29].

7.1 Complex Immunomodulatory Mechanisms of Action

The precise mechanisms by which exogenously administered IVIG rapidly reverses the pathogenic autoimmune cascade in GBS remain multifaceted:

1. Neonatal Fc Receptor (FcRn) Saturation:

The FcRn receptor plays a critical role in regulating the half-life of circulating IgG. High-dose IVIG therapy overwhelms and completely saturates these limited FcRn receptors with healthy donor IgG. Consequently, the unbound, pathogenic endogenous autoantibodies are left unprotected and are actively routed to lysosomal degradation pathways.

2. Macrophage Receptor Blockade:

IVIG massively saturates activating Fc gamma receptors located on the surface of local tissue macrophages. This physical saturation prevents immune effector cells from executing targeted neural phagocytosis.

3. Anti-Idiotypic Neutralization:

IVIG contains a vast, diverse repertoire of naturally occurring anti-idiotypic antibodies that directly bind to and neutralize the patient’s circulating pathogenic autoantibodies.




Figure 3: **Biochemical Mechanisms of IVIG.** The four primary pathways by which high-dose Intravenous Immunoglobulin multi-directionally arrests autoimmune nerve damage.

8 FIRST-LINE PHARMA COTHERAPY: THERAPEUTIC PLASMA EXCHANGE

Therapeutic Plasma Exchange (PE or PLEX) represents the oldest established, evidencebased immunotherapy for GBS, demonstrating robust evidence for efficacy when implemented in the acute phase of the disease. It is a highly invasive, extracorporeal process requiring specialized apheresis equipment, precise vascular access protocols, and intensive hemodynamic monitoring.

8.1 Mechanism of Action

Unlike IVIG, which actively adds immunomodulatory proteins to the patient's system, PE relies on direct, physical extraction. Blood is continuously withdrawn from the patient through a large-bore central venous catheter and routed through a specialized extracorporeal centrifuge or semipermeable membrane filter [30].

The patient's pathogenic plasma—which contains the offending cross-reactive anti-ganglioside autoantibodies, circulating immune complexes, and free activated complement proteins—is physically discarded. The preserved cellular fraction is subsequently re-infused into the patient alongside an isovolumetric substitution fluid, typically purified human albumin.




Figure 4: **Schematic of the Plasmapheresis Circuit.** The extracorporeal diagram outlines the physical separation and removal of pathogenic autoantibodies, followed by cellular return.

8.2 Protocols and Volumetric Dosing

The standard protocol for plasmapheresis in acute GBS involves exchanging a massive total volume of 200 to 250 milliliters per kilogram of plasma. This extreme fluid turnover is staggered across 4 to 5 separate clinical sessions conducted every other day over the course of one to two weeks. The invasive nature of PE introduces unique procedural complications not seen with IVIG, including rapid, severe hypotension and systemic hypocalcemia induced by citrate-based anticoagulants.

9 COMPARATIVE EFFICACY AND CONTRA INDICATIONS

The selection between IVIG and PE represents the most critical decision matrix in the clinical management of acute GBS. Extensive meta-analyses have consistently demonstrated that there is absolutely no statistically significant difference in the fundamental therapeutic efficacy between the two modalities when appropriately timed.

Both interventions demonstrate clinically equivalent metrics regarding the median time required to regain independent ambulation (approximately 80 percent regain walking ability at six months), the long-term risk of neurological relapse, and overall mortality.

9.1 Logistical Superiority vs. Cost-Effectiveness

Where IVIG and PE drastically diverge is in their logistical execution and infrastructural demands. The risk of treatment discontinuation due to patient intolerance, sudden hemodynamic instability, or technical circuit failure is profoundly higher in the PE group. Consequently, IVIG is the unequivocal first-line therapy in high-income nations. However, in resource-limited settings and developing

healthcare infrastructures, the profound cost disparity (PE being significantly less expensive than IVIG) entirely drives clinical policy, rendering PE the vastly more cost-effective paradigm.

9.2 Contraindicated Modalities

Evidence-based guidelines strictly define several pharmacological approaches that are ineffective or actively detrimental:

Corticosteroid Administration:

The use of systemic corticosteroids represents a historical, albeit entirely discredited, approach to GBS management. Comprehensive data explicitly confirm that corticosteroids provide absolutely no biological or functional benefit in acute GBS and actively delay recovery timelines.

Sequential Combination Therapies:

Aggressively combining therapies—specifically executing PE followed immediately by IVIG—yields no clinically significant extra improvement and dramatically amplifies the cumulative frequency of severe adverse events. Therefore, combining or sequencing PE and IVIG is strictly not recommended.

10 MANAGEMENT OF SEVERE COMPLICATIONS AND SUPPORTIVE CARE

The acute morbidity and mortality associated with GBS rarely stem directly from the primary neural demyelination; rather, they arise from the devastating secondary systemic complications of widespread flaccid paralysis. Intensive, multidisciplinary supportive care is paramount and functions equivalently to immunotherapy in ensuring patient survival.

10.1 Respiratory Failure and ICU Management

Approximately one-third of all hospitalized GBS patients rapidly develop severe diaphragmatic and intercostal muscle weakness, leading to acute hypoventilatory respiratory failure. The decision to transition from supportive oxygenation to mechanical intubation must be preemptive, as clinical deterioration can be exceptionally precipitous.

The standard threshold for preemptive intubation in the ICU is strictly governed by clinical pulmonary function tests, dictating emergent mechanical ventilation if vital capacity drops below critical thresholds. Additional clinical criteria mandating immediate airway capture include severe tachypnea, prominent accessory muscle use, acute hypercarbia, or severe hypoxemia.

10.2 Autonomic Dysfunction

Dysautonomia occurs in over half of severely affected GBS patients due to the intense inflammatory involvement of the sympathetic chain and parasympathetic vagal nerves. This severe autonomic instability manifests as wild fluctuations in blood pressure, resting tachycardia, profound bradycardia (potentially requiring temporary pacing), paralytic ileus, and severe urinary retention. Continuous electrocardiographic and hemodynamic monitoring in an ICU environment is absolutely essential.

10.3 Neuropathic Pain and Rehabilitation

Neuropathic pain is a severe, under-recognized complication resulting from acute inflammation of the sensory nerve roots. Guidelines support the aggressive use of gabapentinoids or tricyclic antidepressants for symptomatic control, emphasizing that standard simple analgesia is fundamentally insufficient. Furthermore, aggressive physical therapy must begin immediately, even while the patient is paralyzed, to prevent permanent muscle contractures and deep vein thrombosis.

11 EMERGING THERAPEUTICS AND CONCLUSIONS

While IVIG and Plasmapheresis have undoubtedly revolutionized GBS outcomes over the past four decades, their fundamental biological inability to reverse existing axonal or myelin damage highlights the urgent, unmet need for targeted, rapid-onset biologics.

Given that the terminal, irreversible nerve damage in GBS is directly mediated by classical complement cascade activation (specifically C3c deposition and MAC formation), complement inhibition represents the most promising therapeutic frontier. Novel monoclonal antibodies engineered to block the classical complement pathway at its absolute inception have demonstrated extraordinary results in clinical trials, showing statistically superior, highly sustained composite clinical outcomes compared to historical IVIG/PE benchmarks.

Furthermore, the second major avenue of therapeutic innovation utilizes targeted monoclonal antibodies to precisely antagonize the Neonatal Fc Receptor (FcRn). By inducing a rapid, highly targeted catabolism of all circulating IgG—including the pathogenic autoantibodies—these agents rapidly drop the systemic titer of the agents directly causing nerve destruction without the massive fluid volumes required by traditional IVIG.

11.1 Strategic Outlook

Ultimately, optimizing GBS outcomes requires a highly synchronized, synergistic protocol: immediate, evidence-based immunomodulatory intervention within the critical therapeutic window, meticulous preemptive ICU-level management of respiratory and autonomic complications, and rigorous physical rehabilitation.

As we advance, the rapid integration of novel, biologically targeted therapies as they transition from clinical trials to the standard of care promises to fundamentally alter the prognostic landscape of this severe neuromuscular disease. With continued research into highly specific molecular inhibitors, finding a way to arrest the paralysis instantly and promote rapid neural regeneration is on the immediate horizon. this will be maybe possible in future.

REFERENCES

1. Leonhard SE, Mandarakas MR, Gondim FAA, et al. Diagnosis and management of Guillain-Barré syndrome in ten steps. *Nat Rev Neurol*. 2019; 15(11): 671-683.
2. Willison HJ, Jacobs BC, van Doorn PA. Guillain-Barré syndrome. *Lancet*. 2016; 388(10045): 717-727.
3. Asbury AK, Cornblath DR. Assessment of current diagnostic criteria for Guillain-Barré syndrome. *Ann Neurol*. 1990; 27(Suppl): S21-24.
4. Goodfellow JA, Willison HJ. Guillain-Barré syndrome: a century of progress. *Nat Rev Neurol*. 2016; 12(12): 723-731.
5. Cornblath DR, et al. European Academy of Neurology/Peripheral Nerve Society Guideline on diagnosis and treatment of Guillain-Barré syndrome. *J Peripher Nerv Syst*. 2023.
6. Sejvar JJ, Baughman AL, Wise M, et al. Population incidence of Guillain-Barré syndrome: a systematic review and meta-analysis. *Neuroepidemiology*. 2011; 36(2): 123-133.
7. McGrogan A, Madle GC, Seaman HE, de Vries CS. The epidemiology of Guillain-Barré syndrome worldwide. *Neuroepidemiology*. 2009; 32(2): 150-163.
8. Webb AJ, Brain SA, Wood R, et al. Seasonal variation in Guillain-Barré syndrome: a systematic review. *J Neurol Neurosurg Psychiatry*. 2015; 86(11): 1196-1201.
9. Bogliun G, Beghi E. Incidence and clinical features of acute inflammatory polyradiculoneuropathy. *Acta Neurol Scand*. 2004; 110(1): 17-23.
10. Hughes RA, Cornblath DR. Guillain-Barré syndrome. *Lancet*. 2005; 366(9497): 1653-1666.
11. Ho TW, Mishu B, Li CY, et al. Guillain-Barré syndrome in northern China. *Brain*. 1995; 118(3): 597-605.
12. Kalita J, Misra UK, Das M. Neurophysiological criteria in the diagnosis of different clinical types of GBS. *J Neurol Neurosurg Psychiatry*. 2008; 79(3): 289-293.
13. 293.
14. Jacobs BC, Rothbarth PH, van der Meché FG, et al. The spectrum of antecedent infections in Guillain-Barré syndrome. *Neurology*. 1998; 51(4): 1110-1115.
15. 1110-1115.

16. Winer JB, Hughes RA, Anderson PN, et al. A prospective study of acute idiopathic neuropathy. *J Neurol Neurosurg Psychiatry*. 1988; 51(5): 613-618.
17. Cao-Lormeau VM, Blake A, Mons S, et al. Guillain-Barré Syndrome outbreak associated with Zika virus infection. *Lancet*. 2016; 387(10027): 1531-1539.
18. Allos BM. Association between *Campylobacter* infection and Guillain-Barré syndrome. *J Infect Dis*. 1997; 176(Suppl 2): S125-128.
19. Tam CC, Rodrigues LC, Petersen I, et al. Incidence of Guillain-Barré syndrome among patients with *Campylobacter* infection. *J Infect Dis*. 2006; 194(1): 9597.
20. Rees JH, Soudain SE, Gregson NA, et al. *Campylobacter jejuni* infection and Guillain-Barré syndrome. *N Engl J Med*. 1995; 333(21): 1374-1379.
21. Yuki N. Infectious origins of, and molecular mimicry in, Guillain-Barré and Fisher syndromes. *Lancet Infect Dis*. 2001; 1(1): 29-37.
22. Kuwabara S. Guillain-Barré syndrome: epidemiology, pathophysiology and management. *Drugs*. 2004; 64(6): 597-610.
23. Sheikh KA, Ho TW, Ortiz JW, et al. Anti-ganglioside autoantibodies in Guillain-Barré syndrome. *Neurology*. 1998; 50(4): 1012-1018.
24. Godschalk PC, Heikema AP, Gilbert M, et al. The crucial role of *Campylobacter jejuni* genes in GBS. *J Clin Invest*. 2004; 114(11): 1659-1665.
25. Yuki N, Susuki K, Koga M, et al. Carbohydrate mimicry between human ganglioside GM1 and *Campylobacter jejuni*. *Proc Natl Acad Sci USA*. 2004; 101(31): 11404-11409.
26. Nyati KK, Prasad KN. Role of *Campylobacter jejuni* infection in the pathogenesis of Guillain-Barré syndrome. *Biomed Res Int*. 2014; 2014: 852195.
27. Willison HJ, Goodyear CS. Glycolipid antigens and autoantibodies in autoimmune neuropathies. *Trends Immunol*. 2013; 34(9): 453-459.
28. Kaida K, Morita D, Kanzaki M, et al. Ganglioside complexes as new environmental antigens in Guillain-Barré syndrome. *J Neuroimmunol*. 2008; 195(12): 112-115.
29. Chiba A, Kusunoki S, Shimizu T, Kanazawa I. Serum IgG antibody to ganglioside GQ1b is a possible marker of MFS. *Ann Neurol*. 1992; 31(6): 677-679.
30. McCarthy N, Giesecke J. Incidence of Guillain-Barré syndrome following infection with *Campylobacter jejuni*. *Am J Epidemiol*. 2001; 153(6): 610-614.
31. Magira EE, Papaioakim M, Nachamkin I, et al. Human leukocyte antigen polymorphisms are associated with resistance to GBS. *Neurology*. 2003; 60(8): 1246-1248.
32. Geleijns K, Laman JD, van Rijs W, et al. Macrophage-directed interventions in Guillain-Barré syndrome. *Ann Neurol*. 2007; 61(6): 584-592.